Edwards Lifesciences announced that it has withdrawn its Global Unilateral Pro‑Innovation (Anti‑Copycatting) Policy (UPIP), a measure that had been the focus of a European Commission antitrust investigation. The company said the policy was no longer necessary after the Commission closed its probe on February 16 2026.
The UPIP, introduced in November 2019, barred the company from supporting physicians and researchers who participated in trials sponsored by competitors, effectively limiting access to clinical data for rival transcatheter aortic valve implantation (TAVI) devices. The investigation began after unannounced inspections in September 2023 and a formal complaint from Indian competitor Meril, which alleged that the policy and certain patent practices were anti‑competitive. The Commission’s inquiry examined whether the UPIP restricted physicians’ freedom to join trials for competing TAVI products, potentially hindering those competitors’ market entry in the European Economic Area.
The Commission concluded its investigation on February 16 2026 without finding wrongdoing, and Edwards Lifesciences immediately withdrew the UPIP. The removal eliminates a regulatory hurdle that had exposed the company to fines of up to 10% of global turnover and restores the ability to collaborate with physicians and researchers without the policy’s constraints. Edwards Lifesciences expressed gratitude for the Commission’s review and reaffirmed its commitment to fair competition and intellectual property protection.
The policy withdrawal comes amid a broader regulatory focus on the medical‑device sector. Earlier in January 2026, the U.S. Federal Trade Commission blocked Edwards Lifesciences’ proposed acquisition of JenaValve Technology, citing concerns about reduced innovation and higher prices. The company’s decision to abandon the UPIP signals a shift toward compliance and a willingness to adjust practices that may have been perceived as anti‑competitive.
Overall, the conclusion of the EU probe and the policy’s removal reduce regulatory risk for Edwards Lifesciences, eliminate the threat of significant fines, and position the company to engage more openly with the clinical community. The move is expected to improve its competitive standing in the TAVI market and may influence future regulatory scrutiny of similar practices in the medical‑device industry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.